Reply

We appreciate Li and Liu1 for their interests in and comments on our article.2 Although most patients with severe coronavirus disease 2019 (COVID-19) have a self-limited disease course, about 10% to 15% subsequently developed critical illness and experienced a high mortality.3,4 In our randomized controlled trial, we evaluated whether the use of ruxolitinib was safe and superior in shortening the time to recovery and in preventing severe COVID-19 from progression. Given below are our point-to-point responses to each of the comments.

Source: Journal of Allergy and Clinical Immunology - September 17, 2020 Category: Allergy & Immunology Authors: Yang Cao, Jia Wei, Gaoxiang Wang, Liting Chen, Hui Luo, Jianfeng Zhou Tags: Correspondence Source Type: research